67. J Pharm Sci. 2018 Jul 25. pii: S0022-3549(18)30449-0. doi:10.1016/j.xphs.2018.07.014. [Epub ahead of print]Correlation Analysis of Potential BCRP Probes in Different Monolayer Systems.Sáfár Z(1), Jani M(2), Makai I(3), Fekete Z(1), Bui A(1), Molnár É(1), PádárP(1), Pratt JR(4), Kis E(1), Beéry E(5), Krajcsi P(6).Author information: (1)Solvo Biotechnology, Gyár utca 2, Budaörs, H-2040 Hungary.(2)Solvo Biotechnology, Gyár utca 2, Budaörs, H-2040 Hungary; Seroscience Kft.Nagyvárad tér 4, Budapest, H-1089 Hungary.(3)Ceva-Phylaxia Zrt, Szállás utca 5, Budapest H-1107 Hungary; SolvoBiotechnology, Gyár utca 2, Budaörs, H-2040 Hungary.(4)MilliporeSigma: 2909 Laclede Avenue, Saint Louis, MO 63103, USA.(5)Beckton Dickinson Hungary Kft, Üveggyár út 3, Környe, H-2851 Hungary; SolvoBiotechnology, Gyár utca 2, Budaörs, H-2040 Hungary.(6)Semmelweis University, Department of Morphology and Physiology. Faculty ofHealth Sciences, 17 Vas u, Budapest H-1088, Hungary; Solvo Biotechnology, Gyárutca 2, Budaörs, H-2040 Hungary. Electronic address: krajcsi@solvo.com.Breast Cancer Resistance Protein (BCRP) is a point of interest in Drug DrugInteraction (DDI) safety testing. Therefore a consensus probe that can be appliedas victim in multiple experimental settings is of great benefit. Identificationof candidates has been driven by the amount and quality of available clinicaldata, and as a result sulfasalazine (SSZ) and rosuvastatin (RVS) have beensuggested. In this paper the in vitro performance of five possible alternativesis evaluated: atorvastatin (AVS), chlorothiazide (CHT), dantrolene (DAN),topotecan (TPT), and teriflunomide (TRF), and benchmarked against SSZ and RVS in reference in vitro assays for BCRP DDI testing. Based on the results TRF isproposed as an alternate in vitro BCRP probe.Copyright © 2018. Published by Elsevier Inc.DOI: 10.1016/j.xphs.2018.07.014 PMID: 30055222 